The Trilogy valve. [Image from the JenaValve website] GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) this year.

The primary endpoint was mortality at 30 days. Secondary endpoints were in-hospital mortality, 1-year mortality, bleeding, major vascular complications, myocardial infarction, stroke, incidence of ...

Significant tricuspid regurgitation (TR) is associated with increased morbidity and mortality. The development of transcatheter valve repair therapies has opened a wide range of opportunities for ...

(MGen) of tycoon Manuel V. Pangilinan has completed its investment agreement with Singapore-based Vena Energy for the construction of a massive solar farm in Pangasinan. MGen, through MGen ...